Q-omics provides the consensus-scored ARF5 profile across patient tissues and cancer cell-line models. ARF5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ARF5 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ARF5 protein abundance shows 21,606 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KICH, COAD, and UCEC as cancer lineages where ARF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARF5 survival associations across molecular data types. ARF5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARF5 RNA expression–survival associations across cancer types. High ARF5 expression shows unfavorable associations in KICH, MESO, ACC, LIHC, LGG and COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ARF5 RNA expression.
This table summarizes ARF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARF5 shows higher tumor expression in COAD, BLCA, KIRC, KIRP, LIHC and HNSC. The COAD box plot shows higher ARF5 RNA expression in tumor versus normal tissue (log2 FC = +0.741, t-test p < 0.001).
This table shows molecular features associated with ARF5 in patient tissues and cancer cell lines. In patient samples, ARF5 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and URINARY_TRACT.
